98 results
8-K
EX-99.1
9c268i8uyd k8ncg
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
nu8 q335h0g795kq4
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
3j2jpe0zeo1zxvzs3
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
33jsp
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
DEFA14A
2o6g9bbe52o1jw ofw
31 May 23
Additional proxy soliciting materials
9:00am
8-K
yf6hrvhyfgw03q3jz
1 May 23
Entry into a Material Definitive Agreement
4:48pm
S-3ASR
3bahsqrvhtblp5y6z9
8 Aug 22
Automatic shelf registration
5:12pm